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ABSTRACT
Some aspects of an obese body habitus may protect against fracture risk (higher bone mineral density [BMD] and greater tissue
padding), while others may augment that risk (greater impact forces during a fall). To examine these competing pathways, we
analyzed data from a multisite, multiethnic cohort of 1924 women, premenopausal or early perimenopausal at baseline. Obesity was
defined as baseline body mass index (BMI)> 30 kg/m2. Composite indices of femoral neck strength relative to fall impact forces
were constructed from DXA‐derived bone size, BMD and body size. Incident fractures were ascertained annually during a median
follow‐up of 9 years. In multivariable linear regression adjusted for covariates, higher BMI was associated with higher BMD but with
lower composite strength indices, suggesting that although BMD increases with greater skeletal loading, the increase is not sufficient
to compensate for the increase in fall impact forces. During the follow‐up, 201 women had fractures. In Cox proportional hazard
analyses, obesity was associated with increased fracture hazard adjusted for BMD, consistent with greater fall impact forces in obese
individuals. Adjusted for composite indices of femoral neck strength relative to fall impact forces, obesity was associated with
decreased fracture hazard, consistent with a protective effect of soft tissue padding. Further adjustment for hip circumference, a
surrogatemarker of soft tissue padding, attenuated the obesity–fracture association. Our findings support that there are at least three
major mechanisms by which obesity influences fracture risk: increased BMD in response to greater skeletal loading, increased impact
forces, and greater absorption of impact forces by soft tissue padding. © 2014 American Society for Bone and Mineral Research.
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Introduction
Obesity has long been thought to protect against osteopo-rosis (1) and fragility fractures,(2) primarily because greater
skeletal loading in obese individuals leads to increased bone
mineral density (BMD)(2,3) and more favorable bone geome-
try.(4,5) However, impact forces in a fall are also greater in obese
individuals because body weight is greater. Thus, for obesity to
reduce fracture risk, the increase in BMD stimulated by greater
skeletal loading has to compensate for greater impact forces.
Unfortunately, both chronic inflammation and type 2 diabetes
are also more prevalent in obese individuals, and both have
deleterious influences on fracture risk;(6–9) therefore the BMD
advantage from greater skeletal loading may not be sufficient to
reduce one’s fracture risk.
In fact, multiple recent studies report that fractures are no less
common in obese individuals than in the non‐obese,(10,11) and
that fracture risk in some body sites (eg, extremities) is actually
increased with obesity,(11–15) challenging the conventional
assumption that obesity protects against fractures. There does,
however, appear to be some protection conferred by obesity
against fractures of the hip and pelvis in these studies.(12–15)
Greater absorption of impact forces by soft tissue padding
around the hip may underlie this relative reduction in hip and
pelvic fracture risk in obese women;(4,11,12,14) however, the role of
soft tissue padding in obesity–fracture associations has not been
empirically examined in longitudinal studies.
To disentangle these disparate effects of obesity and fracture
risk, we tested a series of hypotheses aimed at isolating different
components in the obesity–fracture relationship. We hypothe-
sized that:
1. Obesity would be associated with increased BMD, reflecting
the increased bone mass stimulated by greater skeletal
loading.
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2. Obesity would be associated with reduced bone strength
relative to load (ie, that the BMD benefit of obesity would be
insufficient to compensate for greater fall impact forces).
3. Adjusted for BMD (thus, removing the effects of bodyweight
on BMD), obesity would be associated with increased
fracture risk, reflecting greater fall impact forces (ie, we
hypothesized that, of the remaining pathways, the influence
of body weight on fall impact forces would dominate).
4. Adjusted for bone strength relative to load (thus, removing
the effects of body weight on both BMD and fall impact
forces), obesity would be associated with decreased fracture
risk, reflecting the protective role of soft tissue padding (ie,
we hypothesized that, of the remaining pathways, the
protection provided by soft tissue padding would dominate).
We used data from the Hip Strength Across the Menopause
Transition study to test these hypotheses.
Materials and Methods
Study design and population
The Study of Women’s Health Across the Nation (SWAN) is a
multicenter, multiethnic longitudinal study to characterize the
biological and psychosocial changes that occur during the
menopausal transition. Between 1995 and 1997, a screening
survey to assess study eligibility was conducted in women using
either community‐based or population‐based sampling frames
at each of seven participating clinical sites.(16) Briefly, cohort
entry criteria were as follows: age 42 to 53 years, with intact
uterus and at least one ovary, not using sex steroid hormones at
enrollment, had at least one menstrual period in the 3 months
prior to screening, and self‐identified as either white, African
American, Hispanic, Chinese, or Japanese. Each site recruited at
least 450 eligible women into the cohort in 1996 and 1997,
resulting in an inception cohort of 3302 women.(17,18)
Five sites (Boston, Detroit, Pittsburgh, Los Angeles, and
Oakland) collected DXA scans of the hip and lumbar spine in
all but 46 participants who weighed more than 136 kg (the
scanner weight limit); they constituted the SWAN bone cohort.
All five sites enrolled whites, and each site also enrolled women
belonging to one prespecified minority ethnic group: African
American in Boston, Detroit, and Pittsburgh and Japanese and
Chinese in Los Angeles and Oakland, respectively. The Hip
Strength Across the Menopause Transition study, the focus of
this report, measured femoral neck size using archived hip DXA
scans from the 1960 women in the SWAN bone cohort who had a
baseline and two or more follow‐up scans by follow‐up visit 10
(2006–2007). At baseline, 36 women did not get either bone size
or body size measurements, leaving 1924 women in the analytic
sample (963 white, 503 African American, 238 Japanese, and 220
Chinese). All protocols were approved by Institutional Review
Boards at each site and all participants gave written informed
consent.
Assessment of BMD and bone strength relative to load
Using the OsteoDyne Hip Positioner System (Osteodyne Inc.),
DXA scans of the posterior–anterior lumbar spine and total hip
were acquired at the baseline visit. Hologic QDR 4500 models
were used in Boston, Detroit, and Los Angeles, and QDR 2000
scanners were used in Pittsburgh and Oakland (Hologic Inc.,
Waltham, MA, USA). A standard quality‐control program,
conducted in collaboration with Synarc, Inc. (Newark, CA, USA),
included daily phantom measurements, 6‐month cross‐calibra-
tion with a circulating anthropomorphic spine standard, local site
review of all scans, central review of scans that met problem‐
flagging criteria, and central review of 5% random sample of
scans. The 2D‐projected (areal) BMD in the femoral neck and
lumbar spine were recorded.
As markers of relative bone strength, we employed composite
indices of femoral neck strength relative to load that integrate
BMD, bone size, and (in light of the “supply anddemandbalance”)
body size.(19) They have been shown to predict fracture risk in
white women(19) and in women from a multi‐ethnic cohort,(20)
and unlike BMD, they do not require race/ethnicity information to
do so.(20) Also unlike BMD, differences in the composite strength
indices between diabetics and nondiabetics are consistent with
known differences in fracture risks between these groups.(7) In
addition, unlike BMD, the composite strength indices are
inversely associated with serum C‐reactive protein (CRP) levels,
a marker of chronic inflammation, and partially explain the
increased fracture risk associated with inflammation.(6)
Two bone‐size measurements were made on archived
baseline hip scans using pixel dimensions provided by the
manufacturer: femoral neck axis length (FNAL) and femoral neck
width (FNW) (Fig. 1). The composite indices of femoral neck
strength relative to load were computed using height, weight,
FNAL, FNW, and femoral neck BMD (Fig. 1).(19) Compression
strength index (CSI) reflects the ability of the femoral neck to
withstand axial compressive loads proportional to body weight,
bending strength index (BSI) reflects its ability to withstand
bending forces proportional to body weight, and impact
strength index (ISI) reflects its ability to absorb the energy of
impact in a fall from standing height (which is proportional to the
product of body height and weight).(19) To examine reproduc-
ibility of the composite strength indices, 20 women were
scanned twice after repositioning; the intraclass correlation
coefficient for each index was greater than 0.98.
Incident fracture ascertainment and classification
During each of nine annual follow‐up visits, fractures since the
previous visit were self‐reported using a standardized interview-
er‐administered questionnaire. In all years, the number of
fractures, body site(s), and how fractures occurred were
recorded. SWAN initiated collection of the date of fracture at
follow‐up visit 6. Because dates of fractures were not collected in
the first six follow‐ups, they were imputed using the midpoint
between the participant’s index and previous visits. Fractures
reported at visit 6 and later were confirmed by reviewingmedical
records. Medical records were available for 85% of fractures and
of these, only four fractures (3.8%) could not be confirmed. We
excluded from all analyses factures not typically associated with
osteoporosis, in particular fractures of the face, skull, fingers, and
toes.(21,22) We created two categories of fractures: all fractures
and minimum trauma fractures. Minimum trauma fractures
excluded those that occurred as a result of a fall from a height
greater than 6 inches, in a motor vehicle accident, while moving
fast (eg, bicycling or skating), while playing sports, or from impact
with heavy or fast‐moving projectiles.
Measurement of obesity
At the baseline and each of nine follow‐up visits, height and
weight were measured using a fixed stadiometer and a
digital scale with the participants wearing light clothing and
no shoes. The maximum hip circumference was measured over
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undergarments (if a participant refused, over light clothing)
using a measuring tape with the participants standing with their
feet together. Body mass index (BMI) was calculated as weight
divided by the square of height (kg/m2). Previous studies
suggest nonlinear relationships between BMI and fracture risk.
Therefore, participants were classified into four mutually
exclusive BMI categories: low weight (BMI< 22 kg/m2), normal
weight (22 kg/m2 BMI< 25 kg/m2), overweight (25 kg/m2
BMI< 30 kg/m2), and obese (30 kg/m2 BMI). Only 39 women
(2.0%) had BMI< 18.5 kg/m2 and therefore women with BMI
< 22 kg/m2, which accounted for 22.5% of the analytic sample,
were categorized as low weight.
Other measurements
Participants provided the following information at baseline: age
(years), race/ethnicity, menopause transition stage (premeno-
pause or early perimenopause: no changes versus some changes
in regularity of menses but with no gaps of 3months), physical
activity level (summary score combining intensity with frequency
of active living, home, and recreational physical activity from
modified Baecke interview(23)), prescription medications used,
vitamin D and calcium supplement use, alcohol consumption
(abstainer; infrequent: not abstainer, but 1 drink per week; light
to moderate:> 1 drink per week, but 1 per day; and heavy:> 1
drink per day), smoking history, and comorbidities. Women who
reported use of diabetes medications or had fasting serum
glucose 126mg/dL were classified as diabetic. Serum glucose
was measured from blood drawn after an overnight fast, using a
hexokinase‐coupled reaction (Roche Molecular Biochemicals
Diagnostics, Indianapolis, IN, USA). Serum CRP level was
measured at Medical Research Laboratories (Highland Heights,
KY, USA), using an ultrasensitive rate immunonephelometric
methodwith a lower limit of detection of 0.3mg/L (BN100; Dade‐
Behring, Marburg, Germany). The CRP assay within‐run coeffi-
cient of variation (CV) at CRP concentrations of 0.5 and 22.0mg/L
were 10%–12% and 5%–7%, respectively. During each of the
follow‐up visits, information on use of medications was collected
using interviewer‐administered questionnaires.
Statistical analysis
The first set of analyses was designed to examine the effect of
obesity on BMD and bone strength relative to load, and
examined cross‐sectional associations at the baseline SWAN visit.
We first compared themeans of the five bone strength estimates
(BMD in the lumbar spine and femoral neck, and three composite
indices of femoral neck strength relative to load) across BMI
categories. Although we had expected to see a J‐curve
relationship between BMI and bone strength or fracture hazard,
the preliminary analysis found a graded relationship between
BMI categories and each of the bone strength estimates and
fracture hazard, and we decided to set the low weight group as
the reference group. The linear relationships between BMI and
bone strength estimates were also tested by entering BMI into
the models as a continuous variable rather than a categorical
variable.
Multiple linear regression was used to adjust for the
following potential confounders, which were also measured
at baseline: age (continuous); race/ethnicity; menopause
transition stage (premenopause versus early perimenopause);
smoking status (never, past, current); alcohol use categories
(abstainer, infrequent, light to moderate, heavy); level of
physical activity (above median versus below median); current
use (yes versus no) of medications from the following four
classes (one indicator variable for each): supplementary
vitamin D, supplementary calcium, other bone‐active medi-
cations (oral steroids, chemotherapy for breast cancer,
aromatase inhibitors, antiepileptics), and central nervous
system active medications (tranquilizers, antidepressants,
sedatives, sleeping pills); ever/previous use (yes versus no) of
oral steroids; ever/previous use of sex steroids (oral estrogen/
progesterone, estrogen patches, birth control pills); history of
prior fracture as an adult (after age 20 years); and study site. Use
of osteoporosis medications (bisphosphonates, selective
estrogen receptor modulators, calcitonin, parathyroid hor-
mone, or vitamin D in pharmacological doses) at baseline was
reported by only one participant, and therefore the osteopo-
rosis medications variable was not included in the models.
Dunnett’s method was used to adjust for multiple comparisons
between the low weight (reference category) and the three
higher BMI categories.
Fig. 1. Femoral neck size measurements and formulae to compute
composite femoral neck strength indices. AB is the femoral neck axis
length (FNAL), the distance from the base of the greater trochanter to the
apex of the femoral head, and DE is the femoral neck width (FNW), the
smallest thickness of the femoral neck along any line perpendicular to the
femoral neck axis. C is where the femoral neck axis meets the inner pelvic
rim. Composite femoral neck strength indices were computed using the
following formulae, where BMD refers to the areal (projected 2D) bone
mineral density in the femoral neck obtained from DXA:
Compression Strength Index ðCSIÞ ¼ BMDFNWWeight
Bending Strength Index ðBSIÞ ¼ BMDFNW2FNALWeight
Impact Strength Index ðISIÞ ¼ BMDFNWFNALHeightWeight
All three indices were recorded in units of g/kg‐m.With BMDmeasured in
g/cm2, FNW and FNAL in cm, weight in kg, and height in meters, CSI and
BSI were scaled by 100 to get values in units of g/kg‐m.
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To statistically eliminate the (potentially negative) effects of
chronic inflammation and diabetes from the association
between BMI and bone strength estimates, we added diabetes
status (yes/no) and serum CRP level (which was log‐transformed
to minimize its skew) to the base models, in a second step.
The second set of analyses examined obesity associations
with incidence of fracture over 9 years, and employed Cox
proportional hazard regression with time to first fracture as the
dependent variable, and baseline BMI as primary predictor. The
models were initially adjusted for the same set of baseline
covariates as in the cross‐sectional base model plus use in at
least two consecutive visits during follow up of medications
from the following four classes (using one yes/no indicator
variable for each class): sex steroid hormones; osteoporosis
medications; oral steroids; and other bone‐active medications
(chemotherapy, aromatase inhibitors, antiepileptics) as time‐
invariant covariates. This initial model (the longitudinal base
model) estimated the overall effect of obesity on fracture risk. In
subsequent models, we added select covariates representing
one ormore hypothesized obesity–fracture pathways in order to
statistically eliminate the effects of the hypothesized pathway(-
s), and estimate the obesity–fracture association independent of
the selected pathway(s). We first added BMD to the model to
control for the skeletal loading effect of body weight on BMD.
Next, we separately added each composite index of femoral
neck strength relative to load to the longitudinal base model to
control for the effects of body weight on both bonemass and fall
impact forces. We then further adjusted for log(CRP) and
diabetes to remove any residual effects of diabetes and
inflammation (which are more prevalent in obese individuals),
and thus better isolate the protective effect of soft tissue
padding on fracture risk. In the final model, we added a
surrogate marker of soft tissue padding around the hip, derived
from hip circumference to test if it explained away any
remaining protective effect of obesity on fracture risk. The
surrogate hip soft tissue measure was created as the residual
from race/ethnicity‐specific linear regressions of hip circumfer-
ence on body height.
We conducted all the time‐to‐event analyses for each of two
event types: all fractures and minimum trauma fractures. For
analyses of time to first minimum‐trauma fractures, follow‐up
time was censored at the time of the first trauma‐associated
fracture.(24)
A total of 96 (5.0%) women had one or more covariates
missing and the missing values were imputed by single
imputation using the expectation maximization (EM) algo-
rithm.(25) All analyses were conducted using SAS version 9.3
(SAS Institute, Inc., Cary, NC, USA). Two‐sided p< 0.05 was
considered statistically significant.
Results
Participants were classified into four BMI categories: 432 (22.5%)
were categorized as low weight (BMI< 22 kg/m2), 455 (23.6%) as
normal weight (22 kg/m2 BMI< 25 kg/m2), 469 (24.4%) as
overweight (25kg/m2 BMI< 30 kg/m2), and 568 (29.5%) as
obese (30 kg/m2 BMI). Distributions of characteristics across
BMI categories are shown in Table 1. African American women
and women in early perimenopause were more likely to be in
higher BMI categories. Diabetes, history of previous fracture, less
healthier habits (current smoking and less physically active), and
use of central nervous system (CNS)‐activemedications were also
more prevalent in higher BMI categories, whereas Chinese and
Japanese women and use of supplementary vitamin D and
calcium were more common in lower BMI categories.
Cross‐sectional associations between BMI and estimates
of bone strength
Multivariable‐adjusted means of femoral neck BMD and lumbar
spine BMD increased significantly with increasing BMI categories
(Table 2, base model). In contrast, the adjustedmeans of all three
composite indices of femoral neck strength relative to load
decreased significantly with increasing BMI (all p< 0.001).
Consistent with the graded increase in BMD and graded
decrease in composite strength indices with increasing BMI
categories, BMI as a continuous predictor was also linearly and
positively associated with BMD, and linearly and negatively
associated with the composite strength indices. Adjusting for
diabetes and log(CRP) only slightly diminished the magnitude of
the associations between BMI and the composite indices of
strength relative to load (Table 2). Adjusting for diabetes and
log(CRP) had virtually no impact on the associations between
BMI and either lumbar spine BMD or femoral neck BMD.
Association between baseline BMI and incident fracture
After median follow‐up of 9.0 (interquartile range, 8.9–9.1) years,
201 women (10.5%) had at least one fracture, at a rate of 12.6 per
1000 person‐years. Foot (non‐toe) and ankle were the most
common locations for first incident fracture. In Cox proportional
hazard regression, adjusted for age, race/ethnicity, menopause
transition stage, smoking status, alcohol use, level of physical
activity, use of medications at baseline and during follow‐up,
history of prior fracture as an adult, and study site, fracture hazard
was not significantly associated with BMI (Table 3, base model).
After additional adjustment for femoral neck BMD, obesity was
significantly associated with increased fracture hazard: relative
increment in fracture hazard in obese relative to low weight
women: 89% (95% confidence intervals (CI), 14% to 214%)
(Table 3, model 2a). The relative increment in fracture hazard in
obese women compared to normal weight women was also
statistically significant: 78% (95% CI, 13% to 181%, p¼ 0.01). In
stark contrast, obesity was significantly associated with de-
creased fracture hazard when adjusted instead for any of the
composite indices of femoral neck strength relative to load:
relative decrement in fracture hazard in obese relative to low
weight women was 57% (95% CI, 24% to 76%) after adjusting for
CSI, 41% (95% CI, 1% to 65%) after adjusting for BSI, and 53%
(95% CI, 16% to 74%) after adjusting for ISI (Table 3, model 3). The
relative decrement in fracture hazard in obese women relative to
normal weight women after adjusting for CSI was 39%
(p¼ 0.053). Addition of diabetes and log(CRP) to the model
with CSI minimally affected the associations between BMI and
fracture hazard (Table 3,model 4). Further adjustment for hip soft
tissue attenuated the associations between BMI and fracture
hazard and made them statistically nonsignificant (Table 3,
model 5). Similar results were observed when diabetes, log(CRP),
and hip soft tissue were added to Models 3b and 3c (the models
with BSI and ISI)—data not shown.
Consistent with the graded associations between BMI catego-
ries and fracture hazard in models 2 through 4 (Table 3), BMI as a
continuous predictor was linearly and positively associated with
fracture hazard after adjusting for femoral neck or lumbar spine
BMD (Table 3, models 2a and 2b), but linearly and negatively
associated with fracture hazard after adjusting for composite
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Table 1. Participant Characteristics at the Baseline Visit in the Complete Study Sample and by Body Mass Index Categoriesa
Characteristics
All
(n¼ 1924)
Low weightb
(n¼ 432)
Normalb
(n ¼4 55)
Overweightb
(n¼ 469)
Obeseb
(n¼ 568)
p for
trendc
Age (years) 45.9 (2.7) 45.7 (2.7) 45.9 (2.7) 46.1 (2.7) 45.8 (2.7) 0.47
Height (cm) 162.3 (6.5) 161.0 (6.8) 161.8 (6.5) 163.2 (6.4) 162.8 (6.2) <0.001
Weight (kg) 72.6 (19.3) 52.7 (5.4) 61.6 (5.5) 72.9 (6.9) 96.3 (14.6) <0.001
BMI (kg/m2) 27.5 (6.9) 20.3 (1.3) 23.5 (0.9) 27.3 (1.4) 36.3 (5.1) <0.001
Hip circumference (cm) 105.3 (13.9) 91.2 (4.3) 97.7 (4.5) 105.5 (5.4) 122.0 (11.3) <.0001
Waist circumference (cm) 84.6 (15.2) 68.9 (4.0) 76.0 (4.4) 85.3 (6.7) 103.1 (11.3) <0.001
Race/ethnicity, n (%) <0.001
White 963 (50.1) 185 (42.8) 236 (51.9) 248 (52.9) 294 (51.8)
African American 503 (26.1) 38 (8.8) 69 (15.2) 141 (30.1) 255 (44.9)
Chinese 220 (11.4) 100 (23.2) 72 (15.8) 39 (8.3) 9 (1.6)
Japanese 238 (12.4) 109 (25.2) 78 (17.1) 41 (8.7) 10 (1.8)
Menopause transition stage, n (%)d 0.009
Premenopausal 1087 (56.5) 260 (60.2) 266 (58.5) 264 (56.3) 297 (52.3)
Early perimenopausal 837 (43.5) 172 (39.8) 189 (41.5) 205 (43.7) 271 (47.7)
Smoking Status, n (%) <0.001
Never smoked 1142 (59.8) 280 (65.1) 287 (63.2) 266 (57.2) 309 (55.0)
Ex‐smoker 486 (25.4) 92 (21.4) 112 (24.7) 128 (27.5) 154 (27.4)
Current smoker 283 (14.8) 58 (13.5) 55 (12.1) 71 (15.3) 99 (17.6)
Alcohol consumption, n (%)e <0.001
Abstainer 992 (51.6) 199 (46.3) 218 (48.0) 235 (50.1) 340 (59.9)
Infrequent 179 (9.3) 47 (10.9) 37 (8.2) 41 (8.7) 54 (9.5)
Light to moderate 489 (25.5) 112 (26.1) 125 (27.5) 121 (25.8) 131 (23.1)
Heavy 261 (13.6) 72 (16.7) 74 (16.3) 72 (15.4) 43 (7.6)
Physical activity level, n (%) <0.001
Above median 945 (50.6) 247 (59.1) 257 (57.8) 243 (53.3) 198 (36.2)
Below median 921 (49.4) 171 (40.9) 188 (42.3) 213 (46.7) 349 (63.8)
History of prior fracture as adult, n (%) 353 (18.4) 57 (13.2) 72 (15.8) 101 (21.5) 123 (21.7) <0.001
Current use of medications, n (%)
Supplementary vitamin D 742 (38.6) 177 (41.2) 175 (38.6) 182 (38.8) 208 (36.6) 0.17
Supplementary calcium 863 (44.9) 218 (50.7) 212 (46.7) 208 (44.4) 225 (39.6) <0.001
CNS active medicationsf 199 (10.3) 39 (9.0) 37 (8.1) 47 (10.0) 76 (13.4) 0.01
Other bone‐active medicationsg 44 (2.3) 8 (1.9) 7 (1.5) 13 (2.8) 16 (2.8) 0.17
Previous use of medications, n (%)
Sex steroid hormones 1419 (73.8) 287 (66.4) 330 (72.5) 357 (76.1) 445 (78.4) <0.001
Oral steroids 92 (4.8) 13 (3.0) 20 (4.4) 21 (4.5) 38 (6.7) 0.008
Diabetes mellitus, n (%)h 88 (4.6) 3 (0.7) 7 (1.5) 10 (2.1) 68 (12.0) <0.001
FNAL (cm) 8.97 (0.51) 8.98 (0.54) 8.98 (0.51) 9.01 (0.51) 8.91 (0.48) 0.09
FNW (cm) 2.75 (0.20) 2.73 (0.20) 2.73 (0.20) 2.75 (0.20) 2.78 (0.20) <0.001
Lumbar spine BMD (g/cm2) 1.07 (0.13) 1.00 (0.11) 1.04 (0.12) 1.09 (0.13) 1.13 (0.13) <0.001
Femoral neck BMD (g/cm2) 0.84 (0.13) 0.75 (0.10) 0.80 (0.10) 0.85 (0.11) 0.95 (0.13) <0.001
CSI (g/kg‐m) 3.31 (0.64) 3.90 (0.55) 3.54 (0.47) 3.20 (0.43) 2.76 (0.45) <0.001
BSI (g/kg‐m) 1.02 (0.22) 1.19 (0.21) 1.08 (0.19) 0.98 (0.16) 0.87 (0.16) <0.001
ISI (g/kg‐m) 0.18 (0.04) 0.22 (0.03) 0.20 (0.03) 0.18 (0.02) 0.15 (0.03) <0.001
Abbreviations: BMI, body mass index; CNS, central nervous system; FNAL, femoral neck axis length; FNW, femoral neck width; CSI, compression strength
index; BSI, bending strength index; ISI, impact strength index.
aMean and standard deviation shown for continuous variables and number of participants and percentage shown for categorical variables.
bBMI categories: low weight: BMI< 22, normal: 22 BMI< 25, overweight: 25 BMI< 30, and obese: 30 BMI.
cp value for trend across increasing BMI categories was calculated using the Jonckheere‐Terpstra test.
dWomenwere classified as premenopausal if they had experienced at least onemenstrual period in the last 3 months with no change in the regularity of
their menstrual bleeding during the last year and early perimenopausal if they had experienced at least one menstrual period in the last 3 months with
some change in the regularity of their menstrual bleeding during the last year.
eWomen were classified as abstainer if they consumed no alcohol, infrequent if they consumed less than one drink per week, light to moderate if they
consumed more than one drink per week but less than one drink per day, and heavy if they consumed more than one drink per day.
fCNS active medications include tranquilizers, antidepressants, sedatives, and sleeping pills.
gOther bone‐active medications include oral steroids, chemotherapy for breast cancer, aromatase inhibitors, and antiepileptics.
hWomen who reported use of diabetes medications or had fasting serum glucose 126mg/dL were classified as diabetic.
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indices of femoral neck strength relative to load (Table 3, models
3a and 3c). Similarly, the linear and negative relationship between
BMI (as a continuous predictor) and fracture hazard became
nonsignificant when hip soft tissue was added to the model
(Table 3, model 5).
Association between baseline BMI and incident minimum
trauma fracture
After the 9‐year follow‐up, 82 women (4.3%) had at least one
minimum trauma fracture, at a rate of 5.1 per 1000 person‐years.
Findings for minimum trauma fracture were similar to the ones
for all fracture with respect to the direction andmagnitude of the
associations with BMI (Table 4). However, reflecting the smaller
number of events, fewer associations reached levels of statistical
significance.
Discussion
This study was designed to test multiple hypothesized pathways
by which obesity might affect fracture risk: (1) increased BMD in
response to greater skeletal loading, (2) increased impact forces
in a fall (load), (3) deleterious effects of chronic inflammation and
diabetes (common in obesity) on bone mass, and (4) absorption
of impact forces by soft tissue padding. Using data from a multi‐
ethnic cohort of 1924 women going through the menopause
transition, we demonstrated that although higher BMI was
indeed associated with higher BMD (consistent with previous
studies(2,3)), it is in fact associated with lower indices of bone
strength relative to load. These associations between BMI and
the bone strength estimates were monotonic. These findings
suggest that although obesity may increase BMD, the increase in
bone strength is not commensurate with the increase in fall
impact forces. Further adjustment for the detrimental effects of
diabetes and inflammation did not substantially alter the
associations between high BMI and low bone strength.
We also demonstrated that adjusted for BMD, obesity was
associated with increased fracture hazard. Increased fracture
hazard in obesity, when adjusted for BMD, has been seen in
previous studies(10,26) and is consistent with the hypothesis that
larger fall impact forces in obesity increase fracture risk. We also
demonstrated that obesity was associated with decreased
fracture hazard after adjustment for any of the three composite
indices of bone strength relative to fall impact forces. Since
controlling for the composite indices statistically eliminates the
effects of obesity on both bone strength and fall impact forces
without eliminating the effect of soft tissue padding, this is
consistent with a fracture protection effect of soft tissue padding.
Such a protective role is further supported by the observation
that additional adjustment for a surrogate marker for hip soft
tissue padding attenuated the remaining obesity–fracture
association and made it statistically nonsignificant.
Taken together, these findings provide empirical evidence for
the hypothesized pleiotropic effects of obesity on fracture risk.
First, bone mass increases in response to the excess weight.
Second, obesity increases fracture risk by increasing impact
forces in a fall. The increase in bone mass in obesity is not
commensurate with the increased fall impact forces. Third,
the reduction in bone strength relative to load is to some
degree offset by the protection conferred by increased soft tissue
padding. The balance between these factors determines
the overall fracture risk in an individual.
Because the magnitude of these competing effects can vary
frombody site to body site, the relationship between obesity and
fracture will be both site‐specific and person‐specific. For
instance, the adaptive increase in BMD due to greater skeletal
loading will be more pronounced at weight‐bearing sites such as
the hip and spine than in the forearm and wrist. Similarly, the
protection conferred by soft tissue mass will be greatest at body
sites where it is most abundant, and the localization of soft tissue
can vary from person to person. For instance, gynecoid obesity,
where most fat accumulation is around the hip, should provide
Table 3. Adjusted Associations Between Body Mass Index and Incident Fracture Before and After Controlling for Different Pathwaysa
Normal (22 BMI< 25) Overweight (25 BMI< 30) Obese (30 BMI) BMI as continuous predictor
Ref: Low weight Ref: Low weight Ref: Low weight Per unit BMI increment (kg/m2)
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Base modelb 0.91 (0.58, 1.41) 0.67 1.02 (0.66, 1.59) 0.93 1.01 (0.64, 1.59) 0.97 1.01 (0.98, 1.03) 0.58
Model 2a 1.06 (0.68, 1.67) 0.79 1.32 (0.84, 2.08) 0.22 1.89 (1.14, 3.14) 0.01 1.05 (1.02, 1.07) <.001
Model 2b 1.03 (0.66, 1.62) 0.89 1.27 (0.81, 1.99) 0.30 1.50 (0.93, 2.42) 0.10 1.03 (1.005, 1.06) 0.02
Model 3a 0.70 (0.44, 1.10) 0.12 0.59 (0.36, 0.97) 0.04 0.43 (0.24, 0.76) 0.004 0.96 (0.93, 0.99) 0.006
Model 3b 0.76 (0.48, 1.20) 0.24 0.72 (0.45, 1.16) 0.18 0.59 (0.35, 0.99) 0.048 0.98 (0.95, 1.003) 0.08
Model 3c 0.71 (0.45, 1.13) 0.15 0.63 (0.38, 1.03) 0.07 0.47 (0.26, 0.84) 0.01 0.96 (0.93, 0.99) 0.02
Model 4 0.71 (0.45, 1.13) 0.15 0.62 (0.37, 1.02) 0.06 0.43 (0.23, 0.81) 0.009 0.95 (0.92, 0.99) 0.005
Model 5 0.76 (0.48, 1.22) 0.26 0.72 (0.42, 1.23) 0.23 0.65 (0.31, 1.40) 0.27 0.98 (0.91, 1.04) 0.47
Abbreviations: BMI, body mass index; HR, hazard ratio, CI, confidence intervals.
aResults of Cox proportional hazards analysis with BMI as categorical predictor (reference group: lowweight category, BMI< 22kg/m2) and as continuous
predictor in separate models.
bBase model: age, menopause transition stage, race/ethnicity, study site, physical activity, smoking status and alcohol consumption, history of fracture
since age 20, baseline use of medications (supplementary vitamin D, supplementary calcium, bone‐active medications, central nervous system active
medications, ever/previous use of oral steroids, and ever/previous use of sex steroids) and use of medications during the follow‐up (sex steroid hormones,
osteoporosis medications, oral steroids, and other bone‐active medications).
Model 2a: adjusted for covariates in base model plus femoral neck BMD. Model 2b: adjusted for covariates in base model plus lumbar spine BMD. Model
3a: adjusted for covariates in base model plus compression strength index. Model 3b: adjusted for covariates in base model plus bending strength index.
Model 3c: adjusted for covariates in base model plus impact strength index.
Model 4: adjusted for covariates inmodel 3a plus diabetes status and log (C‐reactive protein). Model 5: adjusted for covariates inmodel 4 plus a surrogate
measure of hip soft tissue.
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protection against hip fractures, but not necessarily protect
against fractures at other appendicular sites. This is consistent
with previous studies which found lower hip fracture risk(4,11,12,14)
but higher risk of fractures elsewhere(11–15) in obese compared to
non‐obese women.
Previous studies have found that both inflammation and
diabetes, which are more prevalent in obesity, have deleterious
effects on bone strength and fracture risk(6–9) and that diabetes
is also associated with increased fall risk.(27,28) The observed
negative associations of obesity with both bone strength
relative to load and fracture risk independent of inflammation
and diabetes in this current study suggests that there are other
direct mechanisms by which obesity is deleterious to bone
health. Adipose tissue is considered an endocrine organ
producing adipokines such as adiponectin and leptin, which
have been implicated in bone metabolism.(29) Increased bone
marrow fat in obesity may also have deleterious effects on
bone.(30) Other possible mechanisms include osteoarthritis
(which increases fall risk),(11,31) prediabetes, hyperlipidemia,
hypertension, and vascular atherosclerosis (which may reduce
blood and oxygen supply to bone), all of which are more
prevalent in obese individuals.
It should be noted that the composite strength indices
employed in this study are structural measures based on
macroscopic measurements from DXA scans and body size
derived from structural engineering principles. The indices
ignore important microscopic features such as differences in
microarchitecture, and a recent case control study did demon-
strate that obesity‐induced improvements in microarchitecture
may also not be commensurate with the increased body
weight.(32) In addition, the strength indices were derived using
the simplifying assumption that the femoral neck is a simple
cylinder and do not take into account other aspects of shape
such as femoral neck‐shaft angle, which may also be influenced
by body composition(4,33) and associated with hip fracture
risk.(34) These other pathways from obesity to fracture risk need
further investigation.
Our study has other limitations to be noted. First, fractures
were self‐reported, but fractures after visit 6 were confirmed by
medical records review. It is still possible that we overlooked
clinically silent vertebral fractures. Also, the exact date of fracture
was not recorded until the medical records review process
began; thus, fractures that occurred prior to that time were
assumed to occur at the midpoint between the current and prior
visit. This could bias our estimates.(35) Second, we employed BMI
as a measure of obesity and did not assess the role of truncal
versus appendicular distribution of fat or distinguish fat mass
from lean mass. We also did not differentiate between visceral
and subcutaneous adipose tissues, each of which may have
different biological implications.(36) Third, the composite
strength indices were designed to quantify bone strength in
the femoral neck, but fractures in the femoral neck were
relatively rare in this cohort of middle‐agedwomen (less than 5%
of all fractures). However, just like low or high BMD in the femoral
neck is a reflection of low or high bone mass more generally,(22)
femoral neck strength indices also reflect bone strength
elsewhere in the individual and predict fracture risk more
generally.(20,37) Fourth, the incidence of fracture was low in this
cohort of middle‐aged women, precluding analyses by specific
locations of bone fractures and limiting our power to detect
residual BMI effects after adjusting for hip soft tissue. Lastly, we
did not take into account the change in BMD or bone strength
indices during follow‐up, which may also be influenced by
obesity. Further studies are warranted to assess the generaliz-
ability of our findings to other populations, such as men, older
postmenopausal women, and younger premenopausal women.
In summary, this study provided empirical evidence for at least
three major mechanisms by which obesity may influence
fracture risk: adaptive increase in BMD, increased impact forces
in a fall, and soft tissue padding to absorb impact forces. Our
findings suggest that the assessment of fracture risk has to go
beyond measurement of BMD to include assessment of bone
strength relative to load and the extent of soft tissue over
potential impact sites.
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